Angiotensin receptor blockers following acute stroke

Expert Review of Cardiovascular Therapy
Denise H Rhoney, Lynette R Moser

Abstract

Elevated blood pressure during the acute stroke period is associated with poor neurologic outcomes; however, treating blood pressure in this setting remains controversial. Interest in modulating the renin-angiotensin system in this setting has gained momentum because of neurohormonal properties, which may provide benefits beyond blood pressure control. The Scandinavian Candesartan Acute Stroke Trial (SCAST) was recently published describing the effects of candesartan in patients with hypertension during the acute stroke period. This study shows that lowering blood pressure with an ARB for 7 days poststroke does not improve 6-month neurologic outcomes. This article provides a context for a continuing discussion regarding the role of blood pressure lowering in patients following acute stroke.

References

Sep 1, 1986·Stroke; a Journal of Cerebral Circulation·M BrittonU de Faire
Mar 3, 1973·British Medical Journal·S StrandgaardN A Lassen
Jan 1, 1997·Stroke; a Journal of Cerebral Circulation·T BrottJ Khoury
Dec 24, 1997·Journal of Human Hypertension·J D Spence
May 4, 2002·Stroke; a Journal of Cerebral Circulation·Jo Leonardi-BeeIST Collaborative Group
Jun 21, 2003·Stroke; a Journal of Cerebral Circulation·Joachim SchraderAcute Candesartan Cilexetil Therapy in Stroke Survivors Study Group
Jan 17, 2004·Stroke; a Journal of Cerebral Circulation·José CastilloAntoni Dávalos
Oct 30, 2004·Stroke; a Journal of Cerebral Circulation·Bruce OvbiageleChelsea Kidwell
Jan 8, 2005·Stroke; a Journal of Cerebral Circulation·Heinrich P MattleGerhard Schroth
Jan 25, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jun LiThomas Unger
Mar 31, 2005·American Journal of Hypertension·José Luis Rodríguez-GarcíaJavier González-Spínola
Apr 22, 2005·Pharmacotherapy·Susan C FaganAdviye Ergul
Oct 29, 2005·Stroke; a Journal of Cerebral Circulation·Mei YongJochen Mau
Feb 10, 2006·Journal of Hypertension·Susan C FaganDavid C Hess
Jun 19, 2008·The Journal of Pharmacology and Experimental Therapeutics·Wieslaw KozakSusan C Fagan
Mar 7, 2009·Stroke; a Journal of Cerebral Circulation·Anna KozakSusan C Fagan
Apr 11, 2009·Stroke; a Journal of Cerebral Circulation·Gillian SareVISTA Collaboration
Aug 5, 2009·Hypertension·Rogelio LeiraTICA Study, Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society
Mar 17, 2010·Lancet Neurology·Peter M RothwellASCOT-BPLA and MRC Trial Investigators
Jul 24, 2010·Stroke; a Journal of Cerebral Circulation·Lewis B MorgensternAmerican Heart Association Stroke Council and Council on Cardiovascular Nursing
Aug 13, 2010·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Tomomi NakamuraShinichiro Uchiyama
Sep 9, 2010·Hypertension·Hisatomi ArimaIntensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial Investigators
Oct 12, 2010·Stroke; a Journal of Cerebral Circulation·William J Powers
Oct 16, 2010·Stroke; a Journal of Cerebral Circulation·Youngchai KoHee-Joon Bae

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.